Theravance Biopharma Azioni (NASDAQ: TBPH)

Ultime notizie per Theravance Biopharma (NASDAQ:TBPH) Azioni

Theravance Biopharma

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

BTIG analyst Julian Harrison maintains Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) with a Buy and raises the price target from $24 to $25.

News

Price Target

Analyst Ratings

TBPH

BTIG Maintains Buy on Theravance Biopharma, Raises Price Target to $25

Theravance Biopharma, Inc.&nbsp;("Theravance Biopharma" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) today announced that Viatris Inc. ("Viatris"), has secured regulatory approval from China's National Medical Products Administration (NMPA) for YUPELRI&#xAE; (revefenacin) inhalation solution, the first once–daily nebulized long–acting muscarinic antagonist (LAMA) approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) in China.
&nbsp;
This approval triggers a one-time $7.5 million milestone from Viatris to Theravance Biopharma, which is expected to be received in Q3 2025. Theravance Biopharma is also eligible for further sales-based milestones of up to $37.5 million and tiered royalties of 14% to 20% on net sales in China. Viatris is responsible for all aspects of development and commercialization of YUPELRI in China.
Today's announcement offers further support for Theravance Biopharma's diversified and improving financial position, which includes $131 million in cash as of March 31, 2025, an additional $225 million from the recent sale of TRELEGY royalties to GSK, 35% of U.S. YUPELRI profits, and up to $150 million in near-term potential TRELEGY milestone payments from Royalty Pharma. It also comes as the Company nears completion of enrollment in the open label portion of CYPRESS, its registrational study of ampreloxetine in symptomatic neurogenic orthostatic hypotension associated with multiple system atrophy. Ampreloxetine is a wholly-owned asset with the potential to address a significant unmet need in this rare neurological disorder.

Government

Regulations

Theravance Biopharma Scores $7.5M Milestone After YUPELRI Inhalation Solution Approved in China for COPD Treatment

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Canaccord Genuity analyst William Plovanic initiated coverage on Artivion, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AORT#NYSE">AORT</a>) with a Buy rating and announced a price target of $35. Artivion shares closed at $28.73 on Monday. <a href="https://www.benzinga.com/quote/AORT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Geoff Meacham initiated coverage on Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) with a Sell rating and announced a price target of $6. Novavax shares closed at $7.03 on Monday. <a href="https://www.benzinga.com/quote/NVAX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>China Renaissance analyst Cindy Wang initiated coverage on Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Buy rating and announced a price target of $353.3. Coinbase shares closed at $261.57 on Monday. <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jones Trading analyst Debanjana Chatterjee initiated coverage on Theravance Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) with a Buy rating and announced a price target of $24. Theravance Biopharma shares closed at $10.75 on Monday. <a href="https://www.benzinga.com/quote/TBPH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Johnson Rice analyst Martin Malloy initiated coverage on Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) with a Buy rating and announced a price target of $20. Venture Global shares closed at $17.40 on Monday. <a href="https://www.benzinga.com/quote/VG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying COIN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/COIN/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17092339/image-264-1024x593.png" alt="" class="wp-image-952292" style="width:603px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17092339/image-264-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17092339/image-264-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17092339/image-264-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17092339/image-264.png 1092w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/45968628/wall-streets-most-accurate-analysts-weigh-in-on-3-financial-stocks-with-over-15-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Financial Stocks With Over 15% Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Initiation

Markets

AORT

COIN

NVAX

This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Jones Trading analyst Debanjana Chatterjee initiates coverage on Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) with a Buy rating and announces Price Target of $24.

Jones Trading Initiates Coverage On Theravance Biopharma with Buy Rating, Announces Price Target of $24

Legal

VTRS

Theravance, Mylan Reach Settlement With Eugia Over YUPELRI ANDA Patent Litigation

WIIM

Theravance Biopharma shares are trading lower after the company reported worse-than-expected Q1 financial results.

Theravance Biopharma, Inc.&nbsp;("Theravance Biopharma" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) today announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) at the International MSA Congress, taking place May 9-11 in Boston, Massachusetts.
A subgroup analysis selected as a platform presentation focused on patients with Multiple System Atrophy (MSA) in the REDWOOD 0170 study (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4424053-1&amp;h=1190627893&amp;u=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT03829657%3Fterm%3DNCT03829657%26rank%3D1&amp;a=NCT03829657">NCT03829657</a>), an international phase 3, placebo-controlled, double-blind, randomized withdrawal trial, designed to demonstrate clinical worsening in those assigned to placebo. This analysis concluded:
<ul>
<li>Patients with MSA showed clinically meaningful improvement in their nOH symptoms as measured by the OH Symptom Assessment (OHSA) composite score after 16 weeks of open-label treatment with ampreloxetine. After week 6 of randomization, symptoms remained stable in the ampreloxetine group and worsened in the placebo group.</li>
<li>Ampreloxetine treatment was associated with an improvement in functional activities, such as standing or walking for a short time, which was lost after withdrawal to placebo.</li>
<li>The clinical, cardiovascular and neuroendocrine profile of ampreloxetine showed target engagement of residual peripheral autonomic neurons and a sustained standing blood pressure effect, which is consistent with the profile of a selective norepinephrine reuptake inhibitor.</li>
</ul>
An additional analysis from Study 0169 (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4424053-1&amp;h=1512765078&amp;u=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT03750552%3Fterm%3DNCT03750552%26rank%3D1&amp;a=NCT03750552">NCT03750552</a>)&nbsp;presented at the Congress showed that despite treatment with available nOH medications, patients with MSA had the highest nOH symptom burden on entry, which highlights the substantial unmet need for better nOH therapies in this population.
Results from these studies were supportive of the current registrational study in patients with nOH and MSA that is currently ongoing (CYPRESS, <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4424053-1&amp;h=981583793&amp;u=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT05696717%3Fcond%3DNCT05696717%26rank%3D1&amp;a=NCT05696717">NCT05696717</a>).

Theravance Biopharma Presents Analyses Of Previous Phase 3 Program Evaluating Ampreloxetine For Treatment Of Symptomatic nOH At International MSA Congress

Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.23) by 17.39 percent. This is a 200 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $15.39 million which missed the analyst consensus estimate of $15.50 million by 0.72 percent. This is a 6.10 percent increase over sales of $14.50 million the same period last year.

Earnings

Earnings Misses

Theravance Biopharma Q1 EPS $(0.27) Misses $(0.23) Estimate, Sales $15.39M Miss $15.50M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

Results from these initial studies led to the initiation of a Phase 3 confirmatory study (CYPRESS Study 197) addressing&nbsp;nOH in patients with multiple system atrophy, which is currently ongoing.

Theravance To Present New Analyses Of Initial Phase 3 Program Of Ampreloxetine Supporting Selective And Differentiated Pharmacodynamic Profile At AAN Meeting

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) with a Buy and maintains $15 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $15 Price Target

Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.21) by 76.19 percent. This is a 70.59 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $18.75 million which beat the analyst consensus estimate of $17.09 million by 9.73 percent. This is a 6.77 percent increase over sales of $17.57 million the same period last year.

Earnings Beats

Theravance Biopharma Q4 Adj EPS $(0.05) Beats $(0.21) Estimate, Sales $18.75M Beat $17.09M Estimate

ACAD

ADTN

ALEC

AMBA

AMBC

AMSF

ARDT

ARIS

ASTE

ATEC

AVDX

AVNS

BATRA

BATRK

BBSI

BLMN

BXSL

BYND

CAPL

CDNA

CERT

CLDT

CLPT

COCO

COMM

CORT

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRGY

CSAN

CTRI

DHIL

DMRC

DOLE

DORM

EBAY

ECPG

EHTH

ENIC

ENOV

ERII

ESCA

ESTA

EVTC

FTAI

FWRD

GERN

GOGL

GSX Techedu Inc. American Depositary Shares

GOTU

GRBK

HCAT

HNST

IBTA

IMCR

Earnings Scheduled For February 26, 2025

Theravance Biopharma shares are trading higher after the company reported better-than-expected Q3 sales results.

Guidance

Theravance Biopharma Sees FY24 R&D Expense $30M-$36M; Share-Based Compensation $18M-$22M; SG&A $45M-$55M.

Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.23) by 13.04 percent. The company reported quarterly sales of $16.900 million which beat the analyst consensus estimate of $15.344 million by 10.14 percent. This is a 7.69 percent increase over sales of $15.693 million the same period last year.

Theravance Biopharma Q3 2024 Adj. EPS $(0.26) Misses $(0.23) Estimate, Sales $16.900M Beat $15.344M Estimate

ABOS

ABSI

ACNT

AENT

AGEN

AIOT

AIRG

ALTG

AMPS

APEI

AREB

ARMN

ATRA

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

Comments

Theravance Biopharma

Notizie

Ultime notizie per Theravance Biopharma (NASDAQ:TBPH) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO